Patents by Inventor Lesley J. Murray

Lesley J. Murray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for use of MPL ligands with primitive human stem cells
    Patent number: 7416887
    Abstract: Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (CD34+Lin?, CD34+Thy-1+Lin?, and CD34+Lin? Rh123?lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: August 26, 2008
    Assignee: Novartis AG
    Inventors: Lesley J Murray, Judy C Young
  • Methods for use of mpl ligands with primitive human stem cells
    Patent number: 6916470
    Abstract: Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (CD34+Lin?, CD34+Thy-1+Lin?, and CD34+Lin?Rh123lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: July 12, 2005
    Assignee: Novartis AG
    Inventors: Lesley J. Murray, Judy C. Young
  • Methods for use of mpl ligands with primitive human stem cells
    Publication number: 20030082805
    Abstract: Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (CD34+Lin−, CD34+Thy-1+Lin−, and CD34+Lin− Rh123lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
    Type: Application
    Filed: October 22, 2001
    Publication date: May 1, 2003
    Inventors: Lesley J. Murray, Judy C. Young
  • Methods for use of Mpl ligands with primitive human stem cells
    Patent number: 6326205
    Abstract: Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (CD34+Lin−, CD34+Thy-1+Lin−, and CD34+Lin− Rh123lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: December 4, 2001
    Assignee: Systemix, Inc.
    Inventors: Lesley J. Murray, Judy C. Young
  • Methods for use of Mpl ligands with primitive human hematopoietic stem cells
    Patent number: 6060052
    Abstract: Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34.sup.+ and CD34.sup.+ sub-populations (CD34.sup.+ Lin.sup.-, CD34.sup.+ Thy-1.sup.+ Lin.sup.-, and CD34.sup.+ Lin.sup.- Rh123.sup.lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
    Type: Grant
    Filed: October 30, 1995
    Date of Patent: May 9, 2000
    Assignee: SyStemix, Inc.
    Inventors: Lesley J. Murray, Judy C. Young